Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Systemic Radioligand Therapy with 177 Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Published:2016-08 Issue:2 Volume:196 Page:382-391
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Heck Matthias M.¹,Retz Margitta¹,D'Alessandria Calogero²,Rauscher Isabel²,Scheidhauer Klemens²,Maurer Tobias¹,Storz Enno¹,Janssen Friederike¹²,Schottelius Margret³,Wester Hans-Jürgen³,Gschwend Jürgen E.¹,Schwaiger Markus²,Tauber Robert¹,Eiber Matthias²

Affiliation:

1. Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

3. Pharmaceutical Radiochemistry, Technical University of Munich, Garching, Germany

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference25 articles.

1. Cancer in Germany 2009/2010, 9th ed;Kaatsch,2013

2. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

3. American Cancer Society: Key Statistics for Prostate Cancer. Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed February 6, 2016.

4. International variation in prostate cancer incidence and mortality rates;Center;Eur Urol,2012

5. Prostate-specific membrane antigen expression in normal and malignant human tissues;Silver;Clin Cancer Res,1997

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Internal dosimetry assessment of beta, beta/auger, and alpha decaying radionuclides in targeted radionuclide therapy for prostate cancer: a simulation study;Physica Scripta;2024-07-30

2. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going;Cancer Treatment Reviews;2024-06

3. Automatic Skeleton Segmentation in CT Images Based on U-Net;Journal of Imaging Informatics in Medicine;2024-04-30

4. Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model;EJNMMI Physics;2024-04-24

5. A Pilot Safety Study of Increased Activities (Doses) of <sup>225</sup>Ac-PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer;Journal of oncology: diagnostic radiology and radiotherapy;2024-03-29